prikaz prve stranice dokumenta Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients
  Preuzmi
PDF 387.45 KB
Znanstveni rad - Izvorni znanstveni rad
Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients
Croatian Medical Journal, 58 (2017), 1; 40-48. https://doi.org/10.3325/cmj.2017.58.40
Pejša, Vlatko; Prka, Željko; Lucijanić, Marko; Mitrović, Zdravko; Piršić, Mario; Jakšić, Ozren; Ajduković, Radmila; Kušec, Rajko

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Pejša, V., Prka, Ž., Lucijanić, M., Mitrović, Z., Piršić, M., Jakšić, O. ... Kušec, R. (2017). Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. Croatian Medical Journal, 58. (1), 40-48. doi: 10.3325/cmj.2017.58.40

Pejša, Vlatko, et al. "Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients." Croatian Medical Journal, vol. 58, br. 1, 2017, str. 40-48. https://doi.org/10.3325/cmj.2017.58.40

Pejša, Vlatko, Željko Prka, Marko Lucijanić, Zdravko Mitrović, Mario Piršić, Ozren Jakšić, Radmila Ajduković i Rajko Kušec. "Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients." Croatian Medical Journal 58, br. 1 (2017): 40-48. https://doi.org/10.3325/cmj.2017.58.40

Pejša, V., et al. (2017) 'Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients', Croatian Medical Journal, 58(1), str. 40-48. doi: 10.3325/cmj.2017.58.40

Pejša V, Prka Ž, Lucijanić M, Mitrović Z, Piršić M, Jakšić O, i sur.. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. Croatian Medical Journal [Internet]. 28.02.2017. [pristupljeno 28.12.2024.];58(1):40-48. doi: 10.3325/cmj.2017.58.40

V. Pejša, et al., "Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients", Croatian Medical Journal, vol. 58, br. 1, str. 40-48, Veljača 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:668434. [Citirano: 28.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:668434
Podaci o radu
Naslov (engleski)Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients
AutorVlatko Pejša
AutorŽeljko Prka
AutorMarko Lucijanić
AutorZdravko Mitrović
AutorMario Piršić
AutorOzren Jakšić
AutorRadmila Ajduković
AutorRajko Kušec
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
AIM: To assess the benefit of rituximab with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-DA-EPOCH) regimen as a first-line treatment for patients with diffuse large B-cell lymphoma (DLBCL) presenting with unfavorable or aggressive features, and autologous stem cell transplantation (ASCT) as a part of the first-line treatment for selected DLBCL patients with additional aggressive features. ----- METHODS: We retrospectively analyzed 75 newly diagnosed DLBCL patients with Ki-67+≥80% or International Prognostic Index ≥2 who were treated with R-DA-EPOCH between 2005 and 2015. Of 24 DLBCL patients with additional aggressive features (Ki-67+≥90% or age-adjusted IPI≥2) who were planned to receive consolidation with ASCT, 17 patients underwent the procedure. We determined the overall response rate (ORR), complete remission (CR), partial remission (PR), 5-year overall survival (OS), and progression free survival (PFS) in all DLBCL patients and specifically those planned to receive ASCT. ----- RESULTS: All 75 patients included in the analysis started one or more cycles of therapy. The ORR, CR, and PR rates were 80%, 55%, and 25%, respectively. The response was non-evaluable in 10 of 75 patients due to treatment discontinuation. The OS and PFS rates for all 75 patients were 70% and 61%, respectively, and 80% and 79%, respectively, for 24 planned-to-receive-ASCT patients. Age (≤65 vs >65 years) had no prognostic impact on OS and PFS (P=0.994 and P=0.827, respectively). ----- CONCLUSION: Our retrospective analysis of one of the largest DLBCL patient cohorts outside the US National Cancer Institute showed that R-DA-EPOCH is a very effective therapeutic option as a first-line treatment of DLBCL patients with unfavorable prognostic features irrespective of their age. ASCT provided additional benefit for DLBCL patients with additional aggressive features.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCroatian Medical Journal
Brojčani podacivol. 58, br. 1, str. 40-48
p-ISSN0353-9504
DOIhttps://doi.org/10.3325/cmj.2017.58.40
URN:NBNurn:nbn:hr:105:668434
Datum objave publikacije2017-02-28
URL dokumentahttps://doi.org/10.3325/cmj.2017.58.40
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 09:10:47